Helix Biopharma Corp. Announces Closing of Private Placement, in Preparation for Institutional Investment and NASDAQ Uplisting

About this update from Helix Biopharma Corp.

[{"type":"text","content":"Helix Biopharma Corp. Announces Closing of Private Placement, in Preparation for Institutional Investment and NASDAQ Uplisting\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Toronto, Ontario (22 August\n2025)\n \n\n –\n \n\n TheNewswire -\n \n\n Helix\nBioPharma Corp. (TSX: “HBP”, OTC: “HBPCF”, FRANKFURT:\n“HBP0”)\n \n\n (\n \n\n “Helix”\n \n\n or the\n \n\n “Company”\n \n\n ), a clinical-stage oncology company shaping a near future\nwhere today’s hard-to-treat cancers are vincible, is pleased to\nannounce that the Company has closed its non-brokered private\nplacement (the\n \n\n “Private\nPlacement”)\n \n\n of\n \n\n 2,222,333\n \n\n common shares of the Company (the\n \n\n “Common Shares”\n \n\n )\nat a price of\n \n\n $0.75 per Common Share for gross\nproceeds of $1,666,750.00 (“\n \n\n the Offering”\n \n\n ).  The Company will launch\nthe next Private Placement once new price protection approval has been\ngranted by the TSX.\n \n\n\n\n Following the closure of a private placement of\n$3,000,000 announced by the Company in its press release dated January\n9, 2025,\n \n\n\n\n i\n \n\n\n\n this Private\nPlacement marks the second phase in Helix’s bridge financing\nstrategy, as the Company advances toward securing a larger\ninstitutional investment. Helix intends to invest the net proceeds of\nthe Private Placement toward near-term development activities and\nworking capital, while building on the Company’s active and\nconstructive discussions with institutional investors, which are\nexpected to culminate in a larger financing round that will support\nHelix’s long-term strategic plan and uplisting on NASDAQ. The\nOffering is subject to final approval of the Toronto Stock Exchange,\nand the Common Shares are subject to a hold period of four months and\none day expiring on December 23, 2025, in accordance with applicable\nsecurities laws. In connection with the closing of the Offering, the\nCompany will pay finders’ fees to certain eligible finders.\n \n\n\n\n This news release does not constitute an offer to sell\nor a solicitation of an offer to buy any of the securities described\nherein in the United States. The securities have not been and will not\nbe register...

More updates from Helix Biopharma Corp.